Targeting the intestinal L-cell for obesity and type 2 diabetes treatment

被引：28

作者：

Albrechtsen, Nicolai Jacob Wewer ^{[1
]}

Kuhre, Rune Ehrenreich ^{[1
]}

Deacon, Carolyn F. ^{[1
]}

Holst, Jens Juul ^{[1
,2
]}

机构：

[1] Univ Copenhagen, Fac Hlth & Med Sci, Sect Translat Metab, NNF Ctr Basic Metab Res, Blegdamsvej 3B, DK-2200 Copenhagen, Denmark

[2] Panum Inst, Dept Biomed Sci, DK-2200 Copenhagen N, Denmark

来源：

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM | 2014年 / 9卷 / 01期

关键词：

appetite regulation; gut hormones; gut-brain axis; L-cell; obesity;

D O I：

10.1586/17446651.2014.862152

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Degradation-resistant glucagon-like peptide-1 (GLP-1) mimetics and GLP-1 enhancers (inhibitors of dipeptidyl peptidase-4, the enzyme which degrades and inactivates GLP-1) have been used for treatment of type 2 diabetes mellitus since 2005-2006. Cutting-edge research is now focusing on uncovering the secretory mechanisms of the GLP-1-producing cells (L-cells) with the purpose of developing agonists that enhance endogenous hormone secretion. Since GLP-1 co-localizes with other anorectic peptides, cholecystokinin, oxyntomodulin/glicentin and peptide YY, L-cell targeting might cause release of several hormones at the same time, providing additive effects on appetite and glucose regulation. In this review, we explore the role of proglucagon-derived peptides and other L-cell co-localizing hormones, in appetite regulation and the mechanism regulating their secretion.

引用

页码：61 / 72

页数：12

共 131 条

[1] The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway [J].

Abbott, CR ;

Monteiro, M ;

Small, CJ ;

Sajedi, A ;

Smith, KL ;

Parkinson, JRC ;

Ghatei, MA ;

Bloom, SR .

BRAIN RESEARCH, 2005, 1044 (01) :127-131

[2] Rectal taurocholate increases L cell and insulin secretion, and decreases blood glucose and food intake in obese type 2 diabetic volunteers [J].

Adrian, T. E. ;

Gariballa, S. ;

Parekh, K. A. ;

Thomas, S. A. ;

Saadi, H. ;

Al Kaabi, J. ;

Nagelkerke, N. ;

Gedulin, B. ;

Young, A. A. .

DIABETOLOGIA, 2012, 55 (09) :2343-2347

[3] HUMAN DISTRIBUTION AND RELEASE OF A PUTATIVE NEW GUT HORMONE, PEPTIDE-YY [J].

ADRIAN, TE ;

FERRI, GL ;

BACARESEHAMILTON, AJ ;

FUESSL, HS ;

POLAK, JM ;

BLOOM, SR .

GASTROENTEROLOGY, 1985, 89 (05) :1070-1077

[4] GLP-1 Neurons in the Nucleus of the Solitary Tract Project Directly to the Ventral Tegmental Area and Nucleus Accumbens to Control for Food Intake [J].

Alhadeff, Amber L. ;

Rupprecht, Laura E. ;

Hayes, Matthew R. .

ENDOCRINOLOGY, 2012, 153 (02) :647-658

[5] The role of leptin in the control of insulin-glucose axis [J].

Amitani, Marie ;

Asakawa, Akihiro ;

Amitani, Haruka ;

Inui, Akio .

FRONTIERS IN NEUROSCIENCE, 2013, 7

[6]

[Anonymous], 2013, J DIABETES, V5, P241

[7]

[Anonymous], REGUL PEP

[8] Effect of glucagon-like peptide-2 exposure on bone resorption: Effectiveness of high concentration versus prolonged exposure [J].

Askov-Hansen, Carsten ;

Jeppesen, Palle B. ;

Lund, Pernille ;

Hartmann, Bolette ;

Holst, Jens J. ;

Henriksen, Dennis B. .

REGULATORY PEPTIDES, 2013, 181 :4-8

[9] Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide [J].

Astrup, A. ;

Carraro, R. ;

Finer, N. ;

Harper, A. ;

Kunesova, M. ;

Lean, M. E. J. ;

Niskanen, L. ;

Rasmussen, M. F. ;

Rissanen, A. ;

Rossner, S. ;

Savolainen, M. J. ;

Van Gaal, L. .

INTERNATIONAL JOURNAL OF OBESITY, 2012, 36 (06) :843-854

[10] Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study [J].

Astrup, Arne ;

Rossner, Stephan ;

Van Gaal, Luc ;

Rissanen, Aila ;

Niskanen, Leo ;

Al Hakim, Mazin ;

Madsen, Jesper ;

Rasmussen, Mads F. ;

Lean, Michael E. J. .

LANCET, 2009, 374 (9701) :1606-1616

← 1 2 3 4 5 6 7 8 9 10 →